GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: Meda (STO:MEDAA) has established an affiliate in Hong Kong. At the end of last year, Meda opened its China affiliate based in Beijing. Meda will begin by commercializing two of its well-established products in Hong Kong; Elidel for the treatment of atopic dermatitis (eczema) and azelastine for the treatment of allergic rhinitis (AR).
